<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>239457</rcn>
  <id>101069326</id>
  <acronym>microMESH</acronym>
  <teaser>Despite tremendous progress in the treatment of several malignancies, glioblastoma continues to be the less curable form of any cancer with an overall average survival of 20 months from diagnosis. In this PoC, an interdisciplinary team of engineers, biotechnologists and...</teaser>
  <objective>Despite tremendous progress in the treatment of several malignancies, glioblastoma continues to be the less curable form of any cancer with an overall average survival of 20 months from diagnosis. In this PoC, an interdisciplinary team of engineers, biotechnologists and technology-transfer experts will work to prove that a ground-breaking drug delivery implant  microMESH  can be engineered to deploy intracranially a chemo-immuno-combination therapy to eradicate glioblastoma and minimize its life-long complications. 
microMESH will be engineered to deliver chemotherapeutic drugs (taxanes) and monoclonal antibodies (anti-CD47), that normally would not cross the blood brain barrier, uniformly and deep in the tumor bed. microMESH will comprise two physically distinct compartments  a micrometric network of poly(lactic-co-glycolic acid) (PLGA) strands, carrying taxane molecules; a poly(vinyl alcohol) (PVA) microlayer, encapsulating anti-CD47. Upon deposition on the tumor mass, the PVA microlayer will dissolve in a few days releasing directly on the tumor margins anti-CD47 while the thin and flexible PLGA network will progressively conform to the surrounding surface, establishing an intimate interaction with the malignant cells, and release taxanes in a sustained fashion over several weeks. While taxanes will prevent the rapid proliferating glioblastoma cells from growing, anti-CD47 will stimulate the removal of cancer cells by resident and infiltrating immune cells. 
The success of this PoC will result in a preclinically validated microMESH for the treatment of newly diagnosed and recurrent glioblastoma. Upon subsequent completion of GLP toxicological and cGMP manufacturing studies, microMESH will advance to a Phase 1/2 trial expected to start as early as 2024. In this space, companies with validated Phase 1/2 assets have market capitals ranging from 50M to 400M. A successful microMESH could lead to revenues of 10M /year starting already in 2027.</objective>
  <title>Preclinical validation and market analysis of a microMESH implant for brain cancer eradication</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>150000</ecMaxContribution>
  <startDate>2022-07-01</startDate>
  <endDate>2024-12-31</endDate>
  <ecSignatureDate>2022-05-10</ecSignatureDate>
  <duration>30</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101069326</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-01-03 10:47:16</sourceUpdateDate>
  <contentCreationDate readOnly="true">2022-08-05 17:01:30</contentCreationDate>
  <contentUpdateDate>2024-09-06 17:48:43</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-09-19 14:48:36</lastUpdateDate>
  <relations>
    <associations>
      <call source="corda" type="relatedMasterCall">
        <rcn>55465</rcn>
        <title>ERC-2022-POC1</title>
        <identifier>ERC-2022-POC1</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55465</rcn>
        <title>ERC-2022-POC1</title>
        <identifier>ERC-2022-POC1</identifier>
      </call>
      <organization source="corda" order="1" ecContribution="150000" terminated="false" sme="false" netEcContribution="150000" totalCost="0" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1908748</rcn>
        <id>999596447</id>
        <vatNumber>IT09198791007</vatNumber>
        <legalName>FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA</legalName>
        <shortName>IIT</shortName>
        <address>
          <street>VIA MOREGO 30</street>
          <city>GENOVA</city>
          <postalCode>16163</postalCode>
          <country>IT</country>
          <postBox>000</postBox>
          <url>http://www.iit.it</url>
          <geolocation>44.4730202,8.9058798</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/REC</code>
              <title>Research Organisations</title>
              <displayCode readOnly="true">/Research Organisations</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Genova</name>
              <rcn>309641411</rcn>
              <nutsCode>ITC33</nutsCode>
              <parents>
                <region>
                  <name>Liguria</name>
                  <rcn>309641448</rcn>
                  <nutsCode>ITC3</nutsCode>
                  <parents>
                    <region>
                      <name>Nord-Ovest</name>
                      <rcn>309643816</rcn>
                      <nutsCode>ITC</nutsCode>
                      <parents>
                        <region>
                          <name>Italy</name>
                          <rcn>309758504</rcn>
                          <nutsCode>IT</nutsCode>
                          <euCode>IT</euCode>
                          <isoCode>IT</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Italy</name>
              <rcn>309758504</rcn>
              <nutsCode>IT</nutsCode>
              <euCode>IT</euCode>
              <isoCode>IT</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>706226</rcn>
        <id>HORIZON_ERC-2022-POC1</id>
        <code>ERC-2022-POC1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC PROOF OF CONCEPT GRANTS1</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1307003</rcn>
        <id>101069326_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - microMESH (Preclinical validation and market analysis of a microMESH implant for brain cancer eradication)</title>
        <teaser>Glioblastoma (GBM) is the most aggressive and common malignant brain tumor, with an incidence of about 5 cases per 100,000 people annually. Despite aggressive treatment, including surgery, radiation, and chemotherapy, the median survival remains well below 2 years, with a...</teaser>
        <description>periodic</description>
        <sourceUpdateDate>2025-05-23 15:22:03</sourceUpdateDate>
        <contentUpdateDate>2025-05-23 15:22:03</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode readOnly="true">/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
          <associations>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101069/101069326_PS/picture1.png</uri>
              <alternativeText>microMesh architecture and therapeutic configuration</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">504832</size>
            </webItem>
          </associations>
        </relations>
      </result>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1259805</rcn>
        <id>101069326_130914_PUBLIHORIZON</id>
        <title>ACS Nano</title>
        <details>
          <authors>Daniele Di Mascolo; Irene Guerriero; Cristiano Pesce; Raffaele Spanò; Anna Lisa Palange; Paolo Decuzzi</authors>
          <journalNumber/>
          <journalTitle>ACS Nano</journalTitle>
          <publishedPages/>
          <publishedYear>2023</publishedYear>
          <publisher>American Chemical Society</publisher>
        </details>
        <identifiers>
          <doi>10.1021/ACSNANO.3C01574</doi>
          <issn>1936-0851</issn>
        </identifiers>
        <sourceUpdateDate>2025-04-15 01:27:45</sourceUpdateDate>
        <contentUpdateDate>2025-04-15 01:27:45</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode readOnly="true">/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PEER_REVIEWED_ARTICLE</code>
              <title>Peer reviewed articles</title>
              <displayCode readOnly="true">/Peer reviewed articles</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode readOnly="true">/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/23/53/363/1103</code>
        <title>alcohols</title>
        <displayCode readOnly="true">/natural sciences/chemical sciences/organic chemistry/alcohols</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/37/677</code>
        <title>implants</title>
        <displayCode readOnly="true">/medical and health sciences/medical biotechnology/implants</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="40" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-ERC-POC</code>
        <title>HORIZON ERC Proof of Concept Grants</title>
        <description>HORIZON ERC Proof of Concept Grants</description>
        <displayCode readOnly="true">/HORIZON ERC Proof of Concept Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
